EP1633738A2 - Nouveaux derives de l indole, leur preparation a titre de me dicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr - Google Patents
Nouveaux derives de l indole, leur preparation a titre de me dicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdrInfo
- Publication number
- EP1633738A2 EP1633738A2 EP04742556A EP04742556A EP1633738A2 EP 1633738 A2 EP1633738 A2 EP 1633738A2 EP 04742556 A EP04742556 A EP 04742556A EP 04742556 A EP04742556 A EP 04742556A EP 1633738 A2 EP1633738 A2 EP 1633738A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- radicals
- optionally substituted
- radical
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the present invention relates to new indole derivatives, their preparation process, the new intermediates obtained, their application as medicaments, the pharmaceutical compositions containing them and the new use of such indole derivatives.
- the subject of the invention is therefore new indole derivatives endowed with inhibitory effects with respect to protein kinases.
- the products of the present invention can thus in particular be used for the prevention or treatment of conditions capable of being modulated by inhibiting the activity of protein kinases.
- the products of the present application as protein kinase inhibitors can thus be used for the treatment or prevention of diseases chosen from the following group: cancers, atherosclerosis, degenerative muscular diseases, obesity, Parkinson's disease, depression, schizophrenia, head trauma, spinal cord injury, Alzheimer's disease, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis and various fibrotic disorders.
- diseases chosen from the following group: cancers, atherosclerosis, degenerative muscular diseases, obesity, Parkinson's disease, depression, schizophrenia, head trauma, spinal cord injury, Alzheimer's disease, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis and various fibrotic disorders.
- the products of the present application as inhibitors of protein kinases can very particularly be used for the treatment or prevention of cancers including in particular breast, colon, lung and prostate cancers.
- Cancer remains a disease for which existing treatments are insufficient.
- Certain protein kinases play an important role in many cancers. The inhibition of such protein kinases is potentially important in cancer chemotherapy, in particular to suppress the growth or survival of tumors.
- the present invention therefore relates to the identification of new products which inhibit such protein kinases.
- the inhibition and regulation of protein kinases constitute in particular a new powerful mechanism of action for the treatment of a large number of solid tumors.
- Such conditions which can be treated by the products of the present application are therefore very particularly solid tumors.
- Such protein kinases belong in particular to the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PLK, PDGFR, tie2, VEGFR, AKT, Raf and Aurora 1 or 2.
- Protein kinases are a family of enzymes that catalyze the phosphorylation of hydroxy groups of specific protein residues such as tyrosine, serine or threonine residues. Such phosphorylations can greatly modify the function of proteins; thus, protein kinases play an important role in the regulation of a wide variety of cellular processes, including in particular metabolism, cell proliferation, cell differentiation or cell survival. Among the various cellular functions in which the activity of a protein kinase is involved, certain processes represent attractive targets for treating certain diseases. As an example, mention may be made in particular of angiogenesis and control of the cell cycle, in which protein kinases can play an essential role. These processes are essential for the growth of solid tumors as well as other diseases.
- Protein kinases participate in signaling events that control the activation, growth and differentiation of cells in response, either to extracellular mediators or to changes in the environment. In general, these kinases belong to two groups: those which preferentially phosphorylate the serine and / or threonine residues and those which preferentially phosphorylate the tyrosine residues
- Serine / threonine kinases are, for example, the protein kinase C isoforms [A. C. Newton, J. Biol.
- Tyrosine kinases include growth factor receptors such as the epidermal growth factor receptor (EGF) [S.Iwashita and M.Kobayashi, Cellular Signaling, 1992, 4, pages 123-132], and cytosolic kinases such as p56tck, p59fYn, ZAP-70 and csk kinases [C. Chan and. al., Ann. Rev. Immunol. , 1994, 12, pages 555-592].
- EGF epidermal growth factor receptor
- cytosolic kinases such as p56tck, p59fYn, ZAP-70 and csk kinases [C. Chan and. al., Ann. Rev. Immunol. , 1994, 12, pages 555-592].
- the protein kinase KDR is cited.
- FAK protein kinase is also cited.
- the protein kinase Tie-2 is also cited.
- the protein kinase Aurora is also cited.
- the protein kinase AKT is also cited.
- the protein kinase IGF1-R is also cited.
- Angiogenesis is the process in which new vessels are formed from already existing vessels. When necessary, the vascular system has the potential to generate a network of new vessels to maintain the proper functioning of tissues and organs.
- Angiogenesis is a complex, multi-step process that includes activation, migration, proliferation and survival of endothelial cells. In adults, angiogenesis is fairly limited, appearing mainly only in the repair processes after injury or vascularization of the endometrium (Merenmies et al., Cell Growth & Differentiation, 8, 3-10, 1997) . Uncontrolled angiogenesis is however found in certain pathologies such as retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, or cancer (solid tumors) (Folkman, Nature Med., 1, 27-31, 1995).
- VEGFR-2 vascular endothelial growth factor receptor 2 , also known as KDR, kinase insert domain receptor, or FLK-1
- FGF-R fibroblast growth factor receptor
- Tie-2 vascular endothelial growth factor receptor 2 , also known as KDR, kinase insert domain receptor, or FLK-1
- VEGFR-2 vascular endothelial growth factor receptor 2 , also known as KDR, kinase insert domain receptor, or FLK-1
- FGF-R fibroblast growth factor receptor
- Tie-2 vascular endothelial growth factor receptor 2
- FLK-1 vascular endothelial growth factor receptor 2
- FGF-R fibroblast growth factor receptor
- VEGFRs Vascular Endothelial Growth Factor receptors
- the VEGFR family includes VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR-3 (Flt4).
- VEGFR-2 receptor which is expressed only in endothelial cells, binds to the angiogenic growth factor VEGF, and thus mediates a transduction signal via activation of its intracellular kinase domain.
- KDR The VEGFR-2 receptor
- KDR inhibitors therefore constitute in particular anti-angiogenic agents.
- Angiogenesis inhibitors could thus be used in the first line against the emergence or regrowth of malignant tumors.
- the inhibition or regulation of VEGFR-2 (KDR) therefore provides a new powerful mechanism of action for the treatment of a large number of solid tumors
- FAK Fluorescence Activated kinase
- FAK is a cytoplasmic tyrosine kinase which plays an important role in transducing the signal transmitted by integrins, a family of heterodimeric cell adhesion receptors.
- FAK and integrins are collocated in perimembrane structures called adhesion plates. It has been shown in numerous cell types that the activation of FAK as well as its phosphorylation on tyrosine residues and in particular its autophosphorylation on tyrosine 397 are dependent on the binding of integrins to their extracellular ligands and therefore induced during cell adhesion [Kornberg L, et al. J. Biol. Chem. 267 (33): 23439-442 (1992)].
- Autophosphorylation on FAK tyrosine 397 represents a binding site for another tyrosine kinase, Src, via its SH2 domain
- FAK activation can also induce the jun NH2-terminal kinase (JNK) signaling pathway and result in the progression of cells to the Gl phase of the cell cycle [Oktay et al., J. Cell. Biol. 145: 1461-1469 1999].
- Phosphatidylinositol-3-OH kinase also binds to FAK on tyrosine 397 and this interaction could be necessary for the activation of PI3-kinase [Chen and Guan, Proc. Nat. Acad. Sci. USA. 91: 10148-10152 1994; Ling et al. J. Cell. Biochem. 73: 533-544 1999].
- the FAK / Src complex phosphorylates different substrates such as paxillin and pl30CAS in fibroblasts [Vuori et al. Mol. Cell. Biol. 16: 2606-2613 1996].
- FAK inhibitors may be useful in the treatment of cancer.
- overexpression of pl25FAK leads to an acceleration of the Gl to S transition, suggesting that pl25FAK promotes cell proliferation [Zhao J.-H et al. J. Cell Biol. 143: 1997-2008 1998].
- FAK has also been shown to promote cell migration in vitro.
- fibroblasts deficient for the expression of FAK (“knockout" mouse for FAK) have a rounded morphology, deficiencies in cell migration in response to chemotactic signals and these defects are eliminated by a reexpression of FAK.
- Tie-2 is a member of a family of tyrosine kinase receptors, specific to endothelial cells. Tie2 is the first receptor with tyrosine kinase activity for which both the agonist (angiopoietin 1 or
- Angl which stimulates receptor autophosphorylation and cell signaling [S. Davis et al (1996) Cell 87, 1161-1169] and the antagonist (angiopoietin 2 or Ang2) [PC Maisonpierre et al. (1997) Science 277, 55-60].
- Angiopoietin 1 can synergize with VEGF in the later stages of neoangiogenesis [AsaharaT. Wax. Res. (1998) 233-240].
- Knockout experiments and transgenic manipulations of Tie2 or Angl expression lead to animals with vascular defects [DJ Dumont et al (1994) Genes Dev. 8, 1897-1909 and C. Suri (1996) Cell 87, 1171-1180].
- Tie2 inhibitors can be used in situations where neovascularization is done inappropriately (i.e. in diabetic retinopathy, chronic inflammation, psoriasis, Kaposi's sarcoma, chronic neovascularization due to macular degeneration, rheumatoid arthritis, childhood hemoangioma and cancer).
- Aurora 2 Many proteins involved in chromosome segregation and spindle assembly have been identified in yeast and Drosophila. The disorganization of these proteins leads to non-segregation of chromosomes and to monopolar or disorganized spindles. Among these proteins, certain kinases, including Aurora and Ipll, originating respectively from S. cerevisiae and from Drosophila, are necessary for the segregation of the chromosomes and the separation of the centrosome. A human analog of yeast Ipl1 has been recently cloned and characterized by different laboratories. This kinase, named aurora2, STK15 or BTAK belongs to the family of serine / threonine kinases. Bischoff et al. have shown that Aurora2 is oncogenic, and is amplified in human colorectal cancers (EMBO J, 1998, 17, 3052-3065). This has also been exemplified in cancers involving epithelial tumors such as breast cancer.
- AKT protein kinase also known as PKB
- PI3K phosphoinositide 3-kinase
- This transduction pathway is involved in multiple cellular functions: regulation of apoptosis, control of transcription and translation, glucose metabolism, angiogenesis and mitochondrial integrity.
- AKT serine / threonine kinase AKT was then identified as a mediator playing a key role in survival induced by growth factors.
- AKT has been shown to inhibit death by various stimuli-induced apoptosis in a number of cell types and tumor cells. In agreement with these findings, it has been shown that AKT could, by phosphorylation of given serine residues, inactivate BAD, GSK3 ⁇ , caspase-9, the transcription factor Forkhead and activate IKKalpha and e-NOS.
- hypoxia has been shown to modulate the induction of VEGF in cells transformed by Ha-ras by activating the PI3K / AKT pathway and involving binding sequence of the transcription factor HIF-1 (hypoxia inducible factor-1) called HRE for “hypoxy-responsive-element”.
- AKT plays a very important role in cancer pathologies. Amplification and / or overexpression of AKT has been reported in many human tumors such as gastric carcinoma (amplification of AKTl), carcinomas of the ovary, breast or pancreas (amplification and overexpression of AKT2) and estrogen receptor deficient carcinomas of the breast as well as androgen-independent prostate carcinomas (AKT3 overexpression). In addition, AKT is activated consistently in all PTEN tumors (- / -), the PTEN phosphatase being deleted or inactivated by mutations in many types of tumors such as carcinomas of the ovary, prostate, endometrium, glioblastomas and melanomas.
- AKT is also involved in the oncogenic activation of bcr-abl (References: Khawaja A., Nature 1999, 401, 33-34; Cardone et al. Nature 1998, 282, 1318-1321; Kitada S. et al., Am J Pathol 1998 Jan; 152 (1): 51-61; Mazure NM et al. Blood 1997, 90, 3322-3331; Zhong H. et al. Cancer Res. 2000, 60, 1541-1545).
- IGF-I-R Insulin Growth Factor-1 Receptor
- IGF-I-R is a transmembrane receptor with tyrosine kinase activity which firstly binds to IGFI but also to IGFII and insulin with a lower affinity.
- the binding of IGFI to its receptor leads to oligomerization of the receptor, activation of tyrosine kinase, intermolecular autophosphorylation and phosphorylation of cellular substrates.
- IRS1 and Shc main substrates: IRS1 and Shc.
- the receptor activated by its ligand induces mitogenic activity in normal cells.
- IGF-IR plays a role important in so-called abnormal growth.
- IGF-IR is often found overexpressed in many tumor types (breast, colon, lung, sarcoma %) and its presence is often associated with a more aggressive phenotype.
- IGF-I-R is necessary for the establishment and maintenance of the phenotype transformed in vitro and in vivo [Baserga R, Exp. Cell. Res., 1999, 253, pages 1-6].
- the kinase activity of IGF-I-R is essential for the transformation activity of several oncogenes: EGFR, PDGFR, the grand T antigen of the SV40 virus, activated Ras, Raf, and v-Src.
- Expression of IGF-I-R in normal fibroblasts induces a neoplastic phenotype, which can then lead to tumor formation in vivo.
- the expression of IGF-I-R plays an important role in the independent growth of the substrate.
- IGF-I-R has also been shown to be a protector in chemotherapy-, radiation--induced apoptosis, and cytokine-induced apoptosis.
- the inhibition of endogenous IGF-IR by a dominant negative, the formation of triple helix or the expression of an antisense causes a suppression of the transforming activity in vitro and the decrease in the growth of tumors in the animal models.
- the present application thus particularly relates to new inhibitors of the VEGFR-2 receptor (KDR) which can be used in particular for the anti-angiogenic treatment in oncology.
- KDR VEGFR-2 receptor
- the present invention also relates to novel FAK receptor inhibitors which can be used. for oncology treatments.
- the present invention also relates to novel Tie-2 receptor inhibitors which can be used for oncology treatments.
- the present invention also relates to novel Aurora receptor inhibitors which can be used for oncology treatments.
- the present invention also relates to novel AKT receptor inhibitors which can be used for oncology treatments.
- the present invention thus also relates to new IGF-1R receptor inhibitors which can be used for treatments in oncology.
- R2 and R3 form with the phenyl radical of the indole radical a carbon ring of 4 to 6 members optionally containing one or more identical or different heteroatoms chosen among 0, N and S, this cycle being optionally substituted
- R4 represents alkyl, alk-NYlY2, alk-CO-NYlY2, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all these radicals being optionally substituted
- R5 represents hydrogen
- Yl and Y2 are such that: either Yl and Y2 which are identical or different represent H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, arylcarboxy, heteroaryl, heteroarylalkyl and heteroarylcarboxy, all these radicals being optionally substituted2, or Yl and form together with the nitrogen atom to which they are linked an optionally substituted amino cyclic radical, all the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aryloxy, arylalkyl, arylcarboxy, heteroaryl, heteroarylalkyl radicals , being optionally substituted by one or more radicals chosen from halogen atoms and hydroxyl, alkoxy, alkyl,
- the products of formula (I) of the present invention do not represent: i) products of formula (I) in which R2 and R3 both represent a nitro radical, the other substituents of said products of formula (I) having the values indicated above, ii) of the products of formula (I) belonging to the formula (F):
- R2 and R3, identical or different, are chosen from the following values hydrogen, COOalkyl, COOaryl, COOalkenyl, COOalkynyl, C02H, halogen, OH, O-perfluoro-alkyl, CONR7R8, CN, COOcycloalkyl, COOheterocyclyl, S02NR7R8, S02alkyl, optionally substituted , it being understood that one of R2 and R3 does not represent hydrogen, and al and a2 are chosen from hydrogen, COOalkyl,
- COOaryl COOalkenyl, COOalkynyl, C02H, halogen, OH, O-perfluoroalkyl, CONR7R8, CN, COOcycloalkyl,
- COOheterocyclyl S02NR7R8, S02alkyl, optionally substituted.
- R4 represents alkyl, alk-NYlY2, alk-C0-NYlY2, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkyl, heteroarylalkyl and arylalkyl, all of these radicals being optionally substituted,
- R5 represents hydrogen, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl optionally substituted,
- Yl and Y2 are such that: either Yl and Y2 which are identical or different represent H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, arylcarboxy, heteroaryl, heteroarylalkyl and heteroarylcarboxy, all these radicals being optionally substituted2, or Yl and form together with the nitrogen atom to which they are linked an optionally substituted amino cyclic radical, all the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aryloxy, arylalkyl, arylcarboxy, heteroaryl, heteroarylalkyl radicals , being optionally substituted by one or more radicals chosen from halogen atoms and hydroxyl, alkoxy, alkyl,
- a subject of the present invention is thus the products of formula (I) as defined above in which RI represents a pyrazolyl or indazolyl radical, these radicals being optionally substituted by one or more radicals chosen from the values indicated in claim 1,
- R2 and R3, identical or different, are chosen from the hydrogen atom, the halogen atoms and the hydroxyl radicals, alkyl optionally substituted by NY1Y2, alkenyl, -0R4, -C0-R4, -0-COR4, -OS ( 0) NR4, -0 (CH2) n-CO-R4, nitro, cyano, aryl, heteroaryl and aryloxy, free, salified carboxy, esterified by an alkyl radical optionally substituted or amidified by a radical NY1Y2 such that either Yl and Y2 are identical or different are chosen from H, the alkyl, alkoxyalkyl, cycloalkyl, phenoxyalkyl, aryl, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylcarboxy and heteroarylcarboxy radicals possibly susbtitu ⁇ s, either Yl and Y
- R4 represents optionally substituted alkyl, alkenyl, cycloalkyl, aryl, heteroaryl and cycloalkylalkyl, all the alkyl, alkenyl, aryl, heteroaryl, aryloxy, cycloalkyl and heterocycloalkyl radicals contained in the above radicals being optionally substituted by one or more radicals chosen from halogen atoms, hydroxyl, alkoxy, alkyl, hydroxyalkyl, carboxyalkyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, phenyl, thienyl, phenoxy, phenoxyalkyl, phenylalkoxy, -NH2, -NH (alk), -N (alk ) 2, -NH-S02-alkyl, -NH (phenyl), -NH (phenylalkyl), free carboxy, salified or esterified by an optionally substituted alkyl radical, -C
- RI can have one to four substituents.
- alkyl radical designates the radicals, linear and optionally branched, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl , isopentyle, hexyle, isohexyle and also heptyle, octyl, nonyle and frequentlyyle as well as their linear or branched position isomers,
- hydroxyalkyl radical denotes the alkyl radicals indicated above substituted by at least one hydroxyl radical
- alkenyl denotes linear or branched radicals containing at most 10 carbon atoms and containing one or more double bonds: mention may in particular be made of radicals vinyl, 1-propenyl, allyl, butenyl, 3-methyl-2-butenyl but also for example septa-, octa-, nona- or deca-dienyl such as for example octa-2, 6-dienyl
- alkynyl designates linear radicals or branched containing at most 10 carbon atoms: one can quote in particular the alkyl radicals described above containing 2 to 10 carbon atoms and containing one or two triple bonds
- alkylthio indicates linear or branched radicals containing at most 6 atoms of carbon such as in particular the methylethyl, ethylthio, propylthio, isopropylthio
- alkylthio radicals are such that the sulfur atom is optionally oxidized to sulfone or sulfoxide by one or two oxygen atoms.
- alkoxy radical denotes linear and optionally branched radicals containing at most 10 carbon atoms, methoxy, ethoxy, propoxy, isopropoxy, linear, secondary or tertiary butoxy, pentoxy or hexoxy as well as their linear or branched position isomers,
- alkenyloxy radical designates linear and branched radicals -O alkenyl with alkenyl as defined above
- NH (alk) and N (alk) (alk) denote amino radicals substituted respectively by one or two alkyl radicals, such alkyl radicals being linear or branched and chosen from the alkyl radicals as defined above, containing preferably at most 4 carbon atoms
- acyl denotes a radical RC (O) - in which R represents a radical chosen from the hydrogen atom, linear or branched alkyl radicals containing at most 6 carbon atoms, optionally amino substituted as defined above, the aryl, heteroaryl, cycloalkyl or heterocycloalkyl radicals, for example the phenyl or pyrrolidinyl radicals:
- the term acyl thus denotes for example in particular formyl radicals, acetyl, propionyl, butanoyl, pentanoyl, hexanoyl radicals , benzoyl and pyrrolidinylcarbonyl
- acylamino designates
- NH (alk) and N (alk) (alk) have the meanings indicated above the term halogen atom denotes chlorine, bromine, iodine or fluorine atoms and preferably chlorine, bromine or fluorine atom, - the terms aryl and heteroaryl denote saturated radicals, respectively carbocyclic and heterocyclic one or more heteroatoms, monocyclic or bicyclic containing at most 12 links, the term carbocyclic or heterocyclic radical monocyclic or bicyclic containing at most 12 links, saturated or unsaturated, containing one or more identical or different heteroatoms chosen from O, N, NH or S, and possibly containing a link -C (O), groups together definitions which follow: the term unsaturated carbocyclic radical denotes in particular a cycloalkyl radical the term cycloalkyl radical denote
- monocyclic heterocyclic radical denotes a saturated or unsaturated radical consisting of 5 or 6 links such that one or more of the links represents an oxygen, sulfur or nitrogen atom: such a heterocyclic or heterocycloalkyl radical thus denotes a carbocyclic radical interrupted by one or more heteroatoms chosen from oxygen, nitrogen or sulfur atoms, it being understood that heterocyclic radicals can contain one or more heteroatoms chosen from oxygen, nitrogen or sulfur atoms and that when these heterocyclic radicals contain more than one heteroatom, the heteroatoms of these heterocyclic radicals can be identical or different.
- bicyclic heterocyclic radical denotes a saturated (heteroaryl) or unsaturated radical consisting of 8 to
- one or more of the links represents an oxygen, sulfur or nitrogen atom and in particular condensed heterocyclic groups containing at least one heteroatom chosen from sulfur, nitrogen and oxygen, for example benzothienyl such as 3-benzothienyl, benzothiazolyl, quinolyl, isoquinolyl, tetralone, benzofuryl, dihydrobenzo-furan, ethylenedioxyphenyl, thianthrenyl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, thionaphthalythyro-tetrohyro-tyrololetro-tyrol, tetro-tyrol, tetro-tyrol, tetro-tyrol, tetro-tyrol, tetro-tyrol, tetro-tyroletro-tyrol, tetro-tyrol, tetro-tyrol, tetro-tyrol, tetro-tyrol, tetro-t
- saturated carbocyclic radical (aryl) designates in particular the phenyl and naphthyl radicals and more particularly the phenyl radical. It may be noted that a carbocyclic radical containing a -C (O) link is for example the tetralone radical.
- alkylphenyl denotes a phenyl radical substituted by one or more alkyl radicals as defined above linear or branched preferably containing at most 4 carbon atoms.
- the carboxy radical (s) of the products of formula (I) can be salified or esterified by various groups known to those skilled in the art, among which there may be mentioned, for example:
- mineral bases such as, for example, an equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris (hydroxymethyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine , arginine, histidine, N-methylglucamine, - among the esterification compounds, alkyl radicals to form alkoxy carbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals may be substituted by radicals chosen, for example, from halogen atoms, hydroxyl, alkoxy, acyl, acyloxy, alky
- the addition salts with mineral or organic acids of the products of formula (I) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulfonic acids such as for example methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, alkyl disulphonic acids such as for example methanedisulphonic acid, alpha acid, beta-ethane-disulphonic acid, arylmonosulphonic acids such as benzenesulphonic acid and aryldisulphonic acids.
- stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same developed formulas, but the different groups of which are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent can be in an axial or equatorial position, and the different possible rotational conformations of ethane derivatives.
- stereoisomerism due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, which is often called geometric isomerism or cis-trans isomerism.
- stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.
- a subject of the present invention is thus the products of formula (I) as defined above in which the substituents of said products of formula (I) are chosen from the values indicated above and in particular the aryl radicals represent the phenyl radicals and naphthyl; the heteroaryl radicals represent the furyl, thienyl, benzothienyl, thianthenyl radicals; pyridyl, pyrazolyl, benzimidazolyl, benzofuran, isobenzofuran, dihydrobenzofuran, quinolinyl, quinolone, adamentyl, isoxazolyl and dihydroquinolinyl; the cycloalkyl radicals represent the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals; the heterocycloalkyl radicals represent the hexahydropyran, piperidyl and morpholino radicals; the radicals heterocycloalky
- R2 and R3, identical or different, are chosen from the hydrogen atom; halogen atoms; hydroxyl radicals; alkyl optionally substituted with NY1Y2; alkenyl; alkoxy; nitro; cyano; furyl; thienyle; benzothienyl; naphthyl; thianthenyl; phenyl; phenoxy and carboxy free, salified, esterified by an alkyl radical or amidified by a NY1Y2 radical, it being understood that R2 and R3 can form, with the indole radical to which they are attached, a 4,5-ethylene dioxybenzimidazole radical or a 4, 5- radical methylene dioxybenzimidazole optionally substituted, with NY1Y2 such that either Yl and Y2 which are identical or different are chosen from the hydrogen atom, the alkoxyalkyl alkyl radicals; phenoxyalkyl; phenyl phenylalkyl; phenylcarboxy; nap
- R4 represents optionally substituted alkyl, alkenyl, cycloalkyl, phenyl and cycloalkylalkyl,
- R2 and R3, identical or different, are chosen from the hydrogen atom, the halogen atoms, the hydroxyl, alkyl and alkoxy radicals, nitro, cyano, phenyl and phenoxy, free, salified carboxy, esterified by an alkyl radical or amidifies by a radical NY1Y2 such that either Yl and Y2 identical or different are chosen from the atom hydrogen, alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl and pyridylcarboxy, ie Yl and Y2 together with the nitrogen atom to which they are attached form a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom by an alkyl or phenyl radical themselves optionally substituted, R4 represents optionally substituted alky
- the present invention thus particularly relates to the products of formula (I) as defined above corresponding to formula (I) in which RI, R2 and R3 are among the meanings indicated above with NY1Y2 such that either Yl and Identical or different Y2 are chosen from the hydrogen atom, alkyl radicals, phenyl, phenylalkyl, cycloalkylalkyle, cycloalkyle, furylalkyle and pyridylcarboxy, that is to say Yl and Y2 form together with the nitrogen atom to which they are linked a pyrrolidinyl, morpholino or piperazinyl radical possibly substituted on the second nitrogen atom by an alkyl radical or phenyl themselves optionally substituted by an NH2, NHAlk, N (Alk) 2 or NHS02Alk radical, a morpholino, furyl or pyridyl radical, said products of formula (I) being in all the possible racemic, enantiomeric
- the present invention thus relates to the products of formula (I) as defined above in which RI represents a pyrazolyl radical optionally substituted by one or two substituents chosen from the values indicated above, the other subtituants R2, R3, R4 and R5 being chosen from the values defined above, the said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomer forms, as well as the addition salts with mineral and organic acids or with bases mineral and organic of said products of formula (I).
- R5 represents a hydrogen atom or optionally substituted alkyl
- NY1Y2 being such that either Yl and Y2 identical or different are chosen from the hydrogen atom, the alkyl and pyridylcarboxy radicals optionally substituted, or • Yl and Y2 form together with the nitrogen atom to which they are linked a pyrrolidinyl radical , pyrazolidinyl, pyrazolinyl, piperidyle, morpholino or piperazinyl optionally substituted on the second nitrogen atom by an alkyl or phenyl radical themselves optionally substituted, all the alkyl, alkoxy and phenyl radicals indicated above being additionally optionally substituted by a NH2, NHAlk, N (Alk) 2, NHS02Alk radical, a morpholino, furyl pyridyl radical or a phenyl radical itself optionally substituted by one or more radicals chosen from halogen atoms and alkyl, free carboxy, salified or esterified, amino, alkylamino,
- R2 and R3 being chosen from the values defined in any one of the preceding claims, said products of formula (I) being in all the possible racemic isomeric, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral acids and organic or with the mineral and organic bases of the said products of formula (I).
- R5 represents a hydrogen atom or optionally substituted alkyl
- NY1Y2 being such that either Yl and Y2 which are identical or different are chosen from the hydrogen atom, the alkyl and pyridylcarboxy radicals optionally substituted, or Yl and Y2 form, together with the nitrogen atom to which they are linked, a pyrrolidinyl radical, pyrazolidinyl, pyrazolinyl, piperidyle, morpholino or piperazinyl optionally substituted on the second nitrogen atom by an alkyl or phenyl radical themselves optionally substituted, all the alkyl, alkoxy and phenyl radicals indicated above being additionally optionally substituted by a NH2, NHAlk, N (Alk) 2, NHS02Alk radical, a morpholino, furyl or pyridyl radical, all the alkyl, Alk and alkoxy radicals indicated above being linear or branched and containing at most 6 carbon atoms, all pyridyl radicals themselves being optionally substitute
- R2 and R3 being chosen from the values defined in any one of the claims, said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomer forms, as well as the addition salts with mineral and organic acids or with the mineral and organic bases of the said products of formula (I).
- a very particular subject of the present invention is the products of formula (I) as defined above in which RI represents a pyrazolyl radical substituted by two substituents W1 and W2 as defined above such that one represents an atom d hydrogen and the other represents the radical OR4 with R4 represents the alkyl, cycloalkyl or phenyl radicals optionally substituted by a radical NH2, NHAlk, N (Alk) 2, NHS02Alk, a morpholino, furyl, pyridyl radical or a phenyl radical itself even optionally substituted by one or more radicals chosen from halogen atoms and amino, alkylamino, dialkylamino, phenylamino, hydroxyl, alkoxy and NHCOalk radicals, all the alkyl, Alk and alkoxy radicals indicated above being linear or branched and containing at most 6 carbon atoms,
- R2 and R3 being chosen from the values defined above, said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
- the present invention thus relates to the products of formula (I) as defined above in which RI represents an indazolyl radical optionally substituted by one or more substituents chosen from the values indicated above, the other subtituants R2, R3, R4 and R5 being chosen from the values defined in any one of the claims, said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with the mineral and organic bases of the said products of formula (I).
- the present invention therefore particularly relates to the products of formula (I) as defined above in which RI represents an indazolyl radical,
- R2 and R3 are such that one represents a hydrogen atom and the other is chosen from the following radicals: the hydrogen atom, the halogen atoms, the alkyl radicals optionally substituted by a NY1Y2, alkoxy radical , cyano and carboxy free, salified, esterified by an alkyl radical or amidified into a radical C0NY1Y2,
- NY1Y2 being such that either Yl and Y2 identical or different are chosen from the hydrogen atom, the alkyl and pyridylcarboxy radicals, or Yl and Y2 form, with the nitrogen atom to which they are linked, a pyrrolidinyl, pyrazolidinyl, pyrazolinyl radical , piperidyle, morpholino or an optionally piperazinyl radical substituted by an alkyl or phenyl radical themselves optionally substituted, all the alkyl, alkoxy and phenyl radicals indicated above being additionally optionally substituted by an NH2, NHAlk, N (Alk) 2 or NHS02Alk radical, a morpholino, furyl radical and pyridyle,
- Alk meaning alkyl, all the alkyl, Alk and alkoxy radicals indicated above being linear or branched and containing at most 4 carbon atoms, all the pyridyl radicals themselves being optionally substituted by a halogen atom, said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with mineral and organic bases of the said products of formula (I).
- R2 and R3 are such that one represents a hydrogen atom and the other is chosen from the following radicals: the hydrogen atom, the halogen atoms, the alkyl radicals optionally substituted by a NY1NY2 radical, the alkoxy radicals optionally substituted by a morpholino radical, the cyano radical and the free, salified carboxy radical, esterified by an alkyl radical or amidifies into a CONY1Y2 radical, NY1Y2 being such that either Yl and Y2 identical or different are chosen from the atom d hydrogen, alkyl, furylalkyl, pyridylcarboxy, pyridylalkyl radicals in which the pyridyl radicals are themselves optionally substituted by a halogen atom, ie Yl and Y2 form with the nitrogen atom to which they are linked a piperazinyl radical optionally substituted by an alkyl or phenyl radical themselves optionally substituted by a radical NHS02
- the present invention particularly relates to the products of formula (I) as defined above, corresponding to the following formulas:
- the present invention particularly relates to the products of formula (I) as defined above, corresponding to the following formulas:
- the present invention also relates to processes for the preparation of the products of formula (I), as defined above.
- the protective groups Z 1 and Z2 can be removed at this stage or later
- R2 'and R3' represent the values of R2 and R3 as defined above for the products of formula (I), in which any reactive functions are possibly protected.
- Wl ', W2', W3 'and W4' represent the values of Wl, W2, W3 and W4 as defined above in which the possible reactive functions are optionally protected, Wl, W2, W3 and W4 therefore representing the possible substituents of RI as defined above for the products of formula (I), ie Wl and W2 when RI represents a pyrrazolyl radical and Wl, W2, W3 and W4 when RI represents an indazolyl radical.
- R2 'and R3' represent the values of R2 and R3 as defined above for the products of formula (I), in which the possible reactive functions are optionally protected.
- R4 ′ represents the values of R4 as defined above for the products of formula (I), in which the possible reactive functions are optionally protected.
- Such products obtained by the above schemes can be products of formula (I) or alternatively intermediates to obtain products of formula (I) or be transformed into other products of formula (I), can be subjected, if desired and if necessary, to one or more of the following transformation reactions, in any order: a) an esterification or amidification reaction of acid function, b) a saponification reaction of ester function in acid function , c) an oxidation reaction of an alkylthio group to the corresponding sulfoxide or sulfone, d) a reaction of transformation of the ketone function into the oxime function, e) a reaction of reduction of the free or esterified carboxy function into the alcohol function, f) a transformation reaction of alkoxy function into hydroxyl function, or of hydroxyl function into alkoxy function, g) an oxidation reaction of alcohol function into aldehyde, acid or ketone function, h) u reaction for converting nitrile radicals to tetrazolyl
- the procedure is preferably as follows:
- Nitrogen protection step using the protective groups known to those skilled in the art, such as the Boc group, operating for example in the presence of a mineral (NaHC0 3 for example) or organic (DMAP) base for example) in an inert organic solvent at a temperature in the region of 20 ° C.
- Deprotonation and boronate formation step using a base such as LDA (lithium diisopropylamide, at a temperature in the region of 0 ° C., in an inert organic solvent such as tetrahydrofuran, and using.
- LDA lithium diisopropylamide
- the procedure is preferably carried out in the presence of an inorganic base such as sodium bicarbonate, in the presence of a catalyst such as palladium complexed with triphenylphosphine, in an inert organic solvent such as toluene or DMF, at a temperature between room temperature and the reflux of the reaction medium.
- an inorganic base such as sodium bicarbonate
- a catalyst such as palladium complexed with triphenylphosphine
- an inert organic solvent such as toluene or DMF
- starting materials used for the preparation of the products of formula (I) according to the present invention some are known and can be obtained commercially or can be prepared according to the usual methods known to those skilled in the art. It is also possible in particular to prepare certain starting products from commercial products for example by subjecting them to one or more of the reactions described above in a) to k), carried out under the conditions also described above.
- amino groups can be protected for example by acetyl, trityl, benzyl, tert-butoxycarbonyl, BOC, benzyloxycarbonyl, phthalimido or other radicals known in the chemistry of peptides,
- the acyl groups such as the formyl group can be protected, for example, in the form of cyclic or non-cyclic ketals or thiocetals such as dimethyl or diethyl ketal or ethylene dioxyketal, or diethylthioketal or ethylenedithioketal, the acid functions of the products described above can be, if desired, amidified by a primary or secondary amine, for example in methylene chloride in the presence, for example, of 1-ethyl-3- (dimethylaminopropyl) carbodiimide hydrochloride at room temperature
- esters formed with easily cleavable esters such as benzyl or tert-butyl esters or esters known in the chemistry of peptides.
- Reactions a) to k) can be carried out, for example, as indicated below.
- the products described above can, if desired, be subject, on the possible carboxy functions, to esterification or amidation reactions which can be carried out according to the usual known methods of the skilled person.
- the amidification reactions can in particular be carried out in the presence of a coupling agent such as a carbodiimide derivative. Examples that may be mentioned are N- (3-dimethylaminopropyl) -N '-ethylcarbodiimide (EDCI), N, N' -diisoproylcarbo-diimide (DIC) or N, N '-dicyclohexyl-carbodiimide.
- EDCI N- (3-dimethylaminopropyl) -N '-ethylcarbodiimide
- DIC N, N' -diisoproylcarbo-diimide
- ester functions into acid functions of the products described above can be, if desired, carried out under the usual conditions known to those skilled in the art, in particular by acid or alkaline hydrolysis, for example with sodium hydroxide or potash in an alcoholic medium such as, for example, in methanol or alternatively 1 hydrochloric or sulfuric acid.
- the saponification reaction can be carried out according to the usual methods known to those skilled in the art, such as for example in a solvent such as methanol or ethanol, dioxane or dimethoxyethane, in the presence of soda or potassium hydroxide.
- sulfoxide function can be promoted by an equimolar mixture of the product containing an alkylthio group and of the reagent such as in particular a peracid.
- sulfone function can be promoted by a mixture of the product containing a group alkylthio with an excess of the reagent such as in particular a peracid.
- the reaction for converting a ketone function into an oxime can be carried out under the usual conditions known to a person skilled in the art, such as in particular an action in the presence of an optionally O-substituted hydroxylamine in an alcohol such as for example ethanol, at room temperature or by heating.
- the possible free or esterified carboxy functions of the products described above can be, if desired, reduced in alcohol function by the methods known to those skilled in the art: the possible esterified carboxy functions can be, if desired, reduced in function alcohol by methods known to those skilled in the art and in particular by lithium aluminum hydride in a solvent such as, for example, tetrahydrofuran or even dioxane or ethyl ether.
- the possible free carboxy functions of the products described above can be, if desired, reduced in alcohol function in particular by boron hydride.
- Any alkoxy functions such as in particular methoxy of the products described above can be, if desired, transformed into a hydroxyl function under the usual conditions known to those skilled in the art, for example by boron tribromide in a solvent such as by for example methylene chloride, with pyridine hydrobromide or hydrochloride or alternatively with hydrobromic or hydrochloric acid in water or trifluoro acetic acid at reflux.
- the possible alcohol functions of the products described above can, if desired, be converted into an aldehyde or acid function by oxidation under the usual conditions known to those skilled in the art, such as for example by the action of manganese oxide to get the aldehydes or Jones reagent to access the acids.
- the optional nitrile functions of the products described above can, if desired, be transformed into tetrazolyl under the usual conditions known to those skilled in the art, such as for example by cycloaddition of a metal azide such as for example the azide of sodium or a trialkyltin azide on the nitrile function as indicated in the method described in the article referenced as follows:
- reaction for converting a carbamate into urea and in particular a sulfonylcarbamate into sulfonylurea can be carried out for example at reflux of a solvent such as for example toluene in the presence of the appropriate amine.
- the products of the present invention are very particularly useful for the prevention, regulation or treatment of diseases requiring anti-angiogenic activity.
- the products of the present invention are particularly useful for the therapy of tumors.
- the products of the invention can also thus increase the therapeutic effects of commonly used anti-tumor agents.
- the products of formula (I) of the present invention therefore very particularly have antiangiogenic properties.
- a more particular subject of the invention is therefore, as medicaments, the products as defined by formula (I), said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the salts of addition with mineral and organic acids or with pharmaceutically acceptable mineral and organic bases of said products of formula (I).
- the subject of the invention is particularly, as medicaments, the products described below in the examples and in particular the products corresponding to the following formulas:
- the present invention relates very particularly as medicaments to the products of formula (I) as defined above, corresponding to the following formulas:
- the invention also relates to pharmaceutical compositions containing as active principle at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and, where appropriate if necessary, a pharmaceutically acceptable carrier.
- compositions containing as active principle at least one of the medicaments as defined above may also, where appropriate, contain active principles of other antimitotic drugs such as in particular those based on taxol, cis-platinum, DNA intercalating agents and the like.
- compositions can be administered by the oral route, by the parenteral route or by the local route as a topical application to the skin and the mucous membranes or by injection by the intravenous or intramuscular route.
- compositions can be solid or liquid and can be presented in all the pharmaceutical forms commonly used in human medicine such as, for example, simple or coated tablets, pills, tablets, capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods.
- the active principle can be incorporated therein into excipients usually used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous vehicles or not, fatty substances of animal or vegetable origin, parafinic derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives.
- the usual dosage which varies according to the product used, the subject treated and the condition in question, can be, for example, from 0.05 to 5 g per day in adults, or preferably from 0.1 to 2 g per day.
- the present invention also relates to the use of the products of formula (I) as defined above or of pharmaceutically acceptable salts of these products for the preparation of a medicament intended for the inhibition of the activity of a protein kinase.
- the present invention also relates to the use of products of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease characterized by the disruption of the activity of a protein kinase.
- a medicament may in particular be intended for the treatment or prevention of a disease in a mammal.
- the present invention also relates to the use defined above in which the protein kinase is a protein tyrosine kinase.
- the present invention also relates to the use defined above in which the protein kinase is chosen from the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF- 1R, KDR, PLK, PDGFR, tie2, VEGFR, AKT, Raf and Aurora 1 or 2.
- the protein kinase is chosen from the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF- 1R, KDR, PLK, PDGFR, tie2, VEGFR, AKT, Raf and Aurora 1 or 2.
- the present invention more particularly relates to the use defined above in which the protein kinase is chosen from KDR, Fak, tie2, Aurora, AKT and IGF-1R.
- the present invention particularly relates to the use defined above in which the protein kinase is KDR.
- the present invention also relates to the use defined above in which the protein kinase is in a cell culture.
- the present invention also relates to the use defined above in which the protein kinase is in a mammal.
- the present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease chosen from the following group: disorders blood vessel proliferation, fibrotic disorders, mesangial cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system disease, retinopathy, psoriasis, arthritis rheumatoid, diabetes, muscle degeneration and cancers.
- a disease chosen from the following group: disorders blood vessel proliferation, fibrotic disorders, mesangial cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system disease, retinopathy, psoriasis, arthritis rheumatoid, diabetes, muscle degeneration and cancers.
- a more particular subject of the present invention is the use of a product of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease chosen from the following group: blood vessel proliferation disorders, fibrotic disorders, mesangial cell proliferation disorders, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
- a disease chosen from the following group: blood vessel proliferation disorders, fibrotic disorders, mesangial cell proliferation disorders, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
- a very particular subject of the present invention is the use of a product of formula (I) as defined above for the preparation of a medicament intended for the prevention or treatment of diseases linked to uncontrolled angiogenesis, for the preparation of a medicament intended for the treatment of diseases in oncology and in particular intended for the treatment of cancers.
- a product of formula (I) as defined above for the preparation of a medicament intended for the prevention or treatment of diseases linked to uncontrolled angiogenesis, for the preparation of a medicament intended for the treatment of diseases in oncology and in particular intended for the treatment of cancers.
- cancers we are interested in the treatment of solid tumors, in the treatment of cancers resistant to cytotoxic agents.
- the present invention also relates to the use of the products of formula (I) as defined above for the preparation of medicaments intended for the chemotherapy of cancers.
- Such drugs intended for cancer chemotherapy can be used alone or in combination.
- the products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or alternatively combination for example with other therapeutic agents.
- Such therapeutic agents can be commonly used anti-tumor agents.
- kinase inhibitors mention may be made of butyrolactone, flavopiridol and 2 (2-hydroxyethylamino) -6-benzylamino-9-methylpurine called olomucine.
- the present invention also relates to products of formula (I) as defined above as inhibitors of one or more protein kinases chosen from KDR, Fak, tie2, Aurora, AKT and IGF-1R.
- the present invention particularly relates to the products of formula (I) as defined above as KDR inhibitors.
- the present invention also relates to the products of formula (I) as defined above as tie2 inhibitors.
- LC / MS analyzes were carried out on a Micromass model LCT device connected to an HP 1100 device.
- the abundance of the products was measured using an HP G1315A diode array detector over a wave range of 200-600 nm and a Sedex 65 light scattering detector.
- Mass spectra mass spectra were acquired over a range of 180 to 800. The data were analyzed using Micromass MassLynx software.
- the separation was carried out on a Hypersil BDS C18 column, 3 ⁇ m (50 ⁇ 4.6 mm), eluting with a linear gradient of 5 to 90% acetonitrile containing 0.05% (v / v) of trifluoroacetic acid ( TFA) in water containing 0.05% (v / v) TFA in 3.5 min at a flow rate of 1 mL / min.
- TFA trifluoroacetic acid
- Method B Purification by LC / MS;
- the products were purified by LC / MS using a Waters FractionsLynx system composed of a Waters model 600 gradient pump, a Waters model 515 regeneration pump, a Waters Reagent Manager dilution pump, a car - Waters model 2700 injector, two Rheodyne model LabPro valves, a Waters model 996 diode array detector, a Waters model ZMD mass spectrometer and a Gilson model 204 fraction collector.
- the system being controlled by Waters FractionLynx software.
- the separation was carried out alternately on two Waters Symmetry columns (C ⁇ 8 , 5 ⁇ M, 19x50 mm, catalog reference 186000210), one column being regenerated by a water / acetonitrile 95/5 (v / v) mixture containing 0, 07% (v / v) trifluoroacetic acid, while the other column is being separated. Elution from the columns was carried out using a linear gradient of 5 to 95% acetonitrile containing 0.07% (v / v) of trifluoroacetic acid in water containing 0.07% (v / v) d trifluoroacetic acid, at a flow rate of 10 ml / min.
- one thousandth of the effluent is separated by an LC Packing Accurate, diluted with methyl alcohol at a flow rate of 0.5 ml / min and sent to the detectors, at a rate of 75% to the diode array detector, and the remaining 25% to the mass spectrometer.
- the rest of the effluent (999/1000) is sent to the fraction collector where the flow is eliminated until the mass of the expected product is detected by the FractionLynx software.
- the molecular formulas of the expected products are provided to the FractionLynx software which triggers the collection of the product when the detected mass signal corresponds to the [M + H] + ion and / or to the [M + Na] + .
- the mass spectra were performed in electronic impact (70eV) on a Finnigan SSQ 7000 spectrometer.
- the NMR spectra were carried out on a BRUKER Avance 300 and BRUKER Avance DRX 400 spectrometer.
- the present invention relates very particularly to the products of formula (I) represented in Table I below and which constitute Examples 1 to ⁇ S-22 of the present invention.
- Example 1 Preparation of 3- (5-cyano-indol-2-yl) indazole
- Step 1 N-Boc- 5 -cyano- indole
- the indole derivative is introduced into THF in a 50 ml flask.
- the borate is added at room temperature under nitrogen, then at L ° C under nitrogen the LDA drop by drop over 20 minutes. Stirred at 0 ° C for 2 hours.
- the reaction medium is neutralized with HCI 2N and extracted with AcOEt. After drying and evaporation of the solvent, 829.3 mg of brown meringue are obtained containing 60% of the expected product, N-Boc-5-cyano-indole-2-boronic acid, and 40% of its analogue without Boc.
- This product is used as is in coupling from step 3.
- NBoc-3-iodo-indazole is placed in solution in DMF.
- N-Boc-5-cyano-indole-2-boronic acid, the NaHCO 3 solution and the Pd catalyst (PPh 3 ) 4 are then added, then the reaction mixture is brought to reflux for 1 hour 30 minutes, poured onto water. and the precipitate formed is filtered. 792 mg of a mixture are thus obtained which is purified by chromatography on a column of silica Si60 (100 parts), eluting with: Cyclohexane / AcOEt 95/5, 90/10, 80/20, 70/30 by volume.
- the crude product is purified by chromatography on silica (Biotage) with an elution gradient CH 2 C1 2 / B 95/5 to 80/20, the solvent B being a ternary mixture CH 2 Cl 2 / CH3 ⁇ H / NH 4 OH 38 / 17/2.
- Examples 2 to 7, 10 and 13 can be prepared as described for Example 1 by replacing, in Stage 1 of Example 1, the 5-cyano indole respectively with the following starting products:
- Example 15 is prepared as described for Example 8 by proceeding according to the same procedure starting from the product of Example 13 instead of the product of Example 1.
- the product of example 14 is prepared as described for example 9 by proceeding according to the same procedure starting from the product of example 11 instead of the product of 1 example 8.
- Example 12 The product of example 12 is prepared as described for example 9 while proceeding according to the same procedure starting from the product of example 8.
- the products of examples 16, 17 and 18 are prepared as described for example 9 by proceeding according to the same procedure starting from the product of Example 15 instead of the product of Example 8.
- 4-amino-3- (indol-2-yl) -pyrazole can be prepared in the following way:
- the red filtration juices are concentrated to dryness under reduced pressure, at a temperature in the region of 40 ° C, and purified by chromatography on a silica column (diameter 10 cm; 1000 g of silica 70-200 ⁇ m; fractions of 1000 ml; eluent : CH 2 C1 2 / Methanol / NH 3 H 2 0 (12/3 / 0.5 by volume)).
- the methyl ester of 3- (1- (phenylsuifonyl) -1H- indole-2yl) -3-oxo propionic acid can be prepared as follows:
- the solution is brought to a pH close to 2 by adding an aqueous solution of 2N hydrochloric acid (about 80 ml), then diluted with 250 ml of water. After decantation, the organic phase is washed with 2 times 250 ml of water, then 250 ml of a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, filtered on paper and concentrated to dryness under reduced pressure at a temperature close to 40 ° C. The viscous brown oil obtained is taken up with 830 ml of methanol and the solution thus obtained is brought to reflux for 2 hours.
- 2N hydrochloric acid about 80 ml
- the solution After 30 minutes at a temperature in the region of 0 ° C, the solution is cooled to a temperature in the region of -0 ° C. About 100 g of dry ice are slowly added to the bright orange solution obtained, then the temperature of the solution is allowed to rise to a temperature close to 12 ° C. The reaction medium is concentrated to 3/4 under reduced pressure at a temperature in the region of 40 ° C. The dark orange syrup obtained is taken up in 50 ml of water and extracted with twice 250 ml of ethyl ether. The aqueous phase is acidified to a pH close to 2 by the addition of 2N hydrochloric acid, then extracted 4 times with ethyl ether.
- N- ⁇ 3- [5- (indol-2-yl) -2H-pyrazol-3-yloxymethyl] - phenyl ⁇ -ketamide can be prepared according to a method analogous to that used in Example 20 for the preparation of 3 - [5- (1H-indol-2-yl) -2H-pyrazol-3-yloxyethyl] -phenol, from N- ⁇ 3- [5- (1-phenylsulfonyl-1H- indol-2-yl ) -2H-pyrazol-3-yloxymethyl] -phenyl ⁇ -acetamide.
- N- ⁇ 3- [5- (1-phenylsulfonyl-1H-indol-2-yl) -2H-pyrazol-3-yloxymethyl] -phenyl ⁇ -acetamide can be prepared according to a method analogous to that used in the example 20 for the preparation of 3- [5- (l-phenylsulfonyl-1H-indol-2-yl) - 2H-pyrazol-3-yloxymethyl] -phenol, from 5- (l- (phenylsuifonyl) -lH-indole -2yl) -pyrazol-3-ol (1 equivalent) and 1-bromomethyl- (3-acetylamino) -phenyl (1 equivalent).
- 2- [5- (3-fluoro-benzyloxy) -1H-pyrazol-3-yl] -1H-indole can be prepared according to a method analogous to that used in Example 20 for the preparation of 3- [5- (1H-indol-2-yl) -2H-pyrazol-3-yloxymethyl] -phenol, from l-phenylsulfonyl-2- [5- (3-fluoro-benzyloxy) -lH-pyrazol-3- yl] - 1H-indole.
- 1-Phenylsulfonyl-2- [5- (3-fluoro-benzyloxy) -1H-pyrazol-3-yl] -1H-indole can be prepared according to a method analogous to that used in Example 20 for the preparation of 3 - [5- (1-phenylsulfonyl-1H-indol-2-yl) -2H- pyrazol-3-yloxymethyl] -phenol, from 5- (1- (phenylsulfonyl) -1H-indole-2yl) - pyrazol-3-ol (1 equivalent) and 1-bromomethyl-3-fluoro-phenyl (1 equivalent).
- Examples 9 and 16 are taken as examples of pharmaceutical preparation, this preparation possibly be carried out if desired with other products in examples in the present application.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0305088A FR2854159B1 (fr) | 2003-04-25 | 2003-04-25 | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
PCT/FR2004/000979 WO2004096792A2 (fr) | 2003-04-25 | 2004-04-22 | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1633738A2 true EP1633738A2 (fr) | 2006-03-15 |
Family
ID=33104394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04742556A Ceased EP1633738A2 (fr) | 2003-04-25 | 2004-04-22 | Nouveaux derives de l indole, leur preparation a titre de me dicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1633738A2 (fr) |
JP (1) | JP2006524668A (fr) |
FR (1) | FR2854159B1 (fr) |
WO (1) | WO2004096792A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
JP2008501628A (ja) * | 2004-06-02 | 2008-01-24 | 武田薬品工業株式会社 | インドール誘導体およびがんの治療用途 |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
JP2008507518A (ja) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎を治療するためのチエノピリジン |
US8399442B2 (en) * | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP2049119A2 (fr) * | 2006-06-29 | 2009-04-22 | Astex Therapeutics Limited | Combinaisons pharmaceutiques du 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
MX2012001653A (es) | 2009-08-07 | 2012-06-19 | Hoffmann La Roche | Derivado de aminopirazol. |
US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
WO2015099127A1 (fr) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Gène mutant de fgfr gardien et médicament ciblant celui-ci |
US10479780B2 (en) | 2015-06-17 | 2019-11-19 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivatives |
EA202091483A1 (ru) * | 2017-12-19 | 2020-10-28 | Бристол-Маерс Сквибб Компани | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr |
US20230116201A1 (en) * | 2020-01-30 | 2023-04-13 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
JP2001122855A (ja) * | 1999-10-27 | 2001-05-08 | Japan Tobacco Inc | インドール化合物及びその医薬用途 |
YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
EP1274706A1 (fr) * | 2000-04-18 | 2003-01-15 | Agouron Pharmaceuticals, Inc. | Pyrazoles permettant d'inhiber des proteines kinases |
WO2003024969A1 (fr) * | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Inhibiteurs des tyrosine kinases |
FR2831537B1 (fr) * | 2001-10-26 | 2008-02-29 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation |
-
2003
- 2003-04-25 FR FR0305088A patent/FR2854159B1/fr not_active Expired - Fee Related
-
2004
- 2004-04-22 EP EP04742556A patent/EP1633738A2/fr not_active Ceased
- 2004-04-22 WO PCT/FR2004/000979 patent/WO2004096792A2/fr active Application Filing
- 2004-04-22 JP JP2006505807A patent/JP2006524668A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO2004096792A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004096792A3 (fr) | 2005-09-15 |
FR2854159A1 (fr) | 2004-10-29 |
FR2854159B1 (fr) | 2008-01-11 |
WO2004096792A2 (fr) | 2004-11-11 |
JP2006524668A (ja) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090253697A1 (en) | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | |
FR2831536A1 (fr) | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr | |
FR2850652A1 (fr) | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases | |
WO2006003276A1 (fr) | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation | |
EP1856043B1 (fr) | 1-h-pyrole-2-carboxamides et imidazole-5-carboxamides et leur utilisation en tant modulateurs des kinases fak, kdr et tie2 pour traiter le cancer | |
EP1845978A1 (fr) | Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation | |
WO2004022553A1 (fr) | DERIVES D'INDOLE OU DE BENZIMIDAZOLE POUR MODULER L'IλB KINASE | |
EP1633738A2 (fr) | Nouveaux derives de l indole, leur preparation a titre de me dicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr | |
FR2896503A1 (fr) | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases | |
FR2884821A1 (fr) | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation | |
EP2448927B1 (fr) | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt | |
EP1841762A1 (fr) | Indoles substitues, compositions les contenant, procede de fabrication et utilisation | |
JP6088491B2 (ja) | 新規1位置換インダゾール誘導体 | |
FR2880891A1 (fr) | Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation | |
EP1590329A1 (fr) | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation | |
FR2907120A1 (fr) | Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7 | |
CA2726666C (fr) | Derives de 2-oxo-alkyl-1-piperazin-2-one, leur preparation et leur application en therapeutique | |
CN101296903A (zh) | 新颖含吲哚的β-激动剂、其制备方法及其作为药物的用途 | |
FR2881742A1 (fr) | Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation | |
FR2831537A1 (fr) | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation | |
EP2185525B1 (fr) | Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique | |
JP6088476B2 (ja) | 新規1位置換インダゾール誘導体からなる医薬 | |
TW214548B (fr) | ||
FR2888579A1 (fr) | Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
17P | Request for examination filed |
Effective date: 20060315 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: MK Payment date: 20060315 Extension state: LV Payment date: 20060315 Extension state: LT Payment date: 20060315 Extension state: HR Payment date: 20060315 Extension state: AL Payment date: 20060315 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BOUCHARD, HERVE Inventor name: UGOLINI, ANTONIO |
|
17Q | First examination report despatched |
Effective date: 20080723 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20100129 |